Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings Of The Fortnight: VCs May Be Up Against Trend Of Eliminating The “Middle-Man”

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by PharmAria, Inception 3, Longitude Capital, Kythera and Intercept.

You may also be interested in...



Genocea Gets An Injection Of Capital As Early-Stage Studies Progress

The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.

Mid-To-Late-Stage Investor Longitude Capital Closes $385M Second Fund

A history of strong returns from the firm, which backs both private and public health care companies, compelled existing investors to return for a new fund. Still, Longitude retained a placement agent to find new limited partners as an “insurance policy.”

Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant

The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS073384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel